Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024

Rhea-AI Summary

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) will report its fourth quarter and full year 2023 financial results on February 6, 2024. The management team will host a live conference call and webcast to discuss the financial results and provide a corporate update. The conference call will be accessible via a provided link, and a live webcast will be available on the Company’s website. A replay will also be available for 30 days following the call.

WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its fourth quarter and full year 2023 financial results on Tuesday, February 6, 2024.

In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 8:00 AM ET on Tuesday, February 6, 2024, to discuss the Company’s financial results and provide a corporate update.

The conference call may be accessed via this link: https://register.vevent.com/register/BI7a0bbbeb53864df9a854d959bbbae709

A live webcast of the conference call will be available in the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations. A replay will be available on the Company’s website approximately two hours after the conference call and will be available for 30 days following the call.

About Deciphera Pharmaceuticals 
Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch-control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Iceland, Israel, Liechtenstein, Macau, New Zealand, Norway, Singapore, Switzerland, Taiwan, The United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and X (@Deciphera).

View source version on businesswire.com: https://www.businesswire.com/news/home/20240130118615/en/

Investor Relations:

Maghan Meyers

Argot Partners

Deciphera@argotpartners.com

212-600-1902

Media:

David Rosen

Argot Partners

David.Rosen@argotpartners.com

212-600-1902

Source: Deciphera Pharmaceuticals, Inc.

FAQ

When will Deciphera Pharmaceuticals report its Q4 and full year 2023 financial results?

Deciphera Pharmaceuticals will report its Q4 and full year 2023 financial results on February 6, 2024.

What is the ticker symbol for Deciphera Pharmaceuticals?

The ticker symbol for Deciphera Pharmaceuticals is DCPH.

How can I access the live conference call and webcast?

The live conference call can be accessed via the provided link: https://register.vevent.com/register/BI7a0bbbeb53864df9a854d959bbbae709. The live webcast will be available on the Company’s website in the 'Events and Presentations' page in the 'Investors' section at https://investors.deciphera.com/events-presentations.

Will there be a replay of the conference call available?

Yes, a replay of the conference call will be available on the Company’s website approximately two hours after the call and will be accessible for 30 days following the call.